1. Avonex [Prescribing information] Cambridge, MA: Biogen, Inc August 2014.
2. Rebif [Prescribing information] Rockland, MA: Serono, Inc. March 2015.
3. Betaseron [Prescribing information] Montville, NJ: Berlex Laboratories. January 2014.
4. Extavia [Prescribing Information] Montville, NJ: Novartis. December 2014.
5. Copaxone [Prescribing information] North Wales, PA: Teva-Neuroscience, Inc. January 2014.
6. Plegridy [Prescribing information]Cambridge, MA: Biogen Idec Inc. August 2014.
7. Mitoxantrone [Prescribing information] North Wales, PA: Teva, March 2012.
8. Aubagio [Prescribing Information] Cambridge, MA: Sanofi Company. October 2014.
9. Gilenya [Prescribing Information] East Hanover, NJ: Novartis Pharmaceuticals; April 2014.
10. Lemtrada [Prescribing information] ] Cambridge, MA: Genzyme, Inc. November 2014.
11. Goodin DS, et al. Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-78.
12. Changing therapy in relapsing multiple sclerosis: considerations and recommendations of a task force of the national multiple sclerosis society. Expert Opinion Paper 2008. (Accessed July 1, 2013 at http://www.nationalmssociety.org.)
13. McEvoy GK, ed. AHFS:Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1143-45, 3678-85, 3687-90.
14. American Hospital Formulary Service Drug Information. Available at: http://www.medicinescomplete.com/mc/ahfs/current/. Accessed June 5, 2015.
15. AHFS Drug Information Updates Web site. Available at: http://www.ahfsdruginformation.com. Accessed June 5, 2015.
16. Fernandez O. Combination therapy in multiple sclerosis. J Neurologic Sci. 2007;259:95-103.
17. Costello F, Stuve O, Weber MS, Zamvil SS, Froham E. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice. Curr Opin Neurol. 2007;20:281-85.
18. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2007;68:977-84.
19. Montalban X. MS treatment: postmarketing studies. J Neurologic Sci. 2007;259:42-45.
20. Federal Register. Determination That Novantrone (Mitoxantrone Hydrochloride) Injection, Equivalent to 25 Milligrams Base/12.5 Milliliter and Equivalent to 30 Milligrams Base/15 Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness / Vol. 76, No. 71 / Wednesday, April 13, 2011Accessed at http://www.gpo.gov/fdsys/pkg/FR-2011-04-13/pdf/2011-8819.pdf on July 1, 2013.
21. Tecfidera [Prescribing Information] Cambridge, MA: Biogen Idec Inc. April 2015.
22. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-1107.
23. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087-97 Kappos L, Radue EW, OConnor P, et al. FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362(5):387-401.
24. Cohen JA, Barkhof F, Comi G, et al. TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362(5):402-415
25. OConnor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Eng J Med. 2011;365:1293-1303.
26. OConnor P, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of teriflunomide in the multiple sclerosis with relapses. Neurology. 2006;66;894-900.
27. Freedman MS, Wolinsky JS, Wamil B, et al. Teriflunomide added to interferon-beta in relapsing multiple sclerosis: A randomized phase II trial. Neurology. 2012; 78:1877-1885.
28. National Comprehensive Cancer Network. Non-Hodgkins Lymphoma Version 2.2014. Available at: http://www.nccn.org/professionals/physician_gls/.pdf.
29. DRUGDEX. System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com/. Accessed June 5, 2015.
30. Glatopa [Prescribing information] Princeton, NJ: Sandoz Inc., June 2015.